Loading clinical trials...
Loading clinical trials...
Affecting the Glycemic Impact of Quaker Instant Oatmeal by Adding OatWell28XF: a Dose-Response Study
The objective of this study is to determine the effect on glycemic responses of adding various doses of OatWell28XF to Quaker Instant Oatmeal in order to: 1) describe the dose-response curve and 2) If possible, identify the minimum level of OatWell28XF which, when added to a serving of Quaker Instant Oatmeal, would result in a glycemic response at least 20% less than that elicited by a β-glucan-free cereal.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
Yes
GI Labs
Toronto, Canada
Start Date
June 1, 2016
Primary Completion Date
August 1, 2016
Completion Date
August 1, 2016
Last Updated
December 7, 2016
40
ACTUAL participants
Oatmeal + OatWell28XF
OTHER
Oatmeal
OTHER
Hot cereal
OTHER
Lead Sponsor
PepsiCo Global R&D
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions